🇺🇸 FDA
Patent

US 10421963

Oligonucleotide therapy for leber congenital amaurosis

granted A61KA61K31/7125A61P

Quick answer

US patent 10421963 (Oligonucleotide therapy for leber congenital amaurosis) held by ProQR Therapeutics II B.V. expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ProQR Therapeutics II B.V.
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/7125, A61P, A61P27/02